Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
Open Access
- 18 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 5 (8) , e10526
Abstract
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)2D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)2D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.Keywords
Funding Information
- American Society of Nephrology (Donal E. Wesson Research Fellowship Award)
- National Heart, Lung, and Blood Institute (K24HL150235)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK114857, R01DK101730, R01DK114158, T32DK007169)
This publication has 38 references indexed in Scilit:
- Osteoporotic FracturesPharmacoEconomics, 2012
- Effect of kidney disease on glucose handling (including genetic defects)Kidney International, 2011
- The Sweet Pee Model for Sglt2 MutationJournal of the American Society of Nephrology, 2011
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- A National Perspective of Medicare Expenditures for Elderly Veterans with Hip FracturesJournal of the American Medical Directors Association, 2008
- Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYPEndocrinology, 2007
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of internal medicine (1960), 2005
- Epidemiology and direct medical costs of osteoporotic fractures in men and women in SwitzerlandOsteoporosis International, 2004
- Hypercalciuria in children with renal glycosuria: Evidence of dual renal tubular reabsorptive defectsThe Journal of Pediatrics, 1992